- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04171505
Retrospective Cohort Study of the Effectiveness of the Prophylactic Vaccine Against the Human Papilloma Virus in the Prevention of Recurrence in Women Who Have Received an Excisional Therapy by HSIL / CIN. (VENUS)
Retrospective Cohort Study to Analyze Whether Prophylactic Vaccination Against HPV Can Reduce the Risk of Recurrence in Women Who Have Received an Excisional Therapy for HSIL / CIN2-3. Recurrence is Defined as the Detection of Infection by the Same HPV Genotype for at Least 6-12 Months (Persistent Infection), and / or Cytological Alteration and / or Cervical and / or Vaginal Histological Lesion of Any Grade (SIL / CIN / VaIN) in Patients With Negative Cotest in the First Post Control.
A retrospective cohort study of women treated by excisional therapy due to HSIL/ CIN at Clínico San Carlos Hospital between 2012-2018. The effectiveness of prophylactic vaccination against HPV in women treated for HPV-related disease will be evaluated. For this purpose, the percentage of cervical lesion recurrence among a group of treated and vaccinated women against HPV between the years 2015-2018 will be compared with a control group of treated and non-vaccinated women against HPV since 2012-2015.
It will be an essential requirement that the patient provide a vaccination card from their health center where there is proof of their immunization status and date of administration.
Inclusion criteria:
- Women older than 18 years who received excisional therapy due to HSIL /CIN injury confirmed histologically.
- Women who sign informed consent.
- Patients with negative results in the first post-surgery control.
- Patients who have received HPV vaccination and provide vaccination card.
Exclusion criteria:
- Women who do not wish or cannot give their informed consent and / or do not comply with the requirements of the study.
- Patients treated by an indication other than HSIL/CIN.
- Patients under immunosuppression conditions.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A retrospective cohort study of women treated by excisional therapy due to HSIL/ CIN at Clínico San Carlos Hospital (Madrid) between 2012-2018. The effectiveness of prophylactic vaccination against HPV in women treated for HPV-linked disease will be evaluated. For this purpose, the percentage of lesional recurrence among a group of treated and vaccinated women against HPV between the years 2015-2018 will be compared with a control group of treated and non-vaccinated women against HPV since 2012-2015. The data will be obtained through the review of clinical records.
Our protocol is explained above:
HPV detection method:
The detection of HPV is performed on a liquid basis by means of the CLARK PAPILOMAVIRUS HUMAN test that detects the presence of the HPV virus (6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 68, 70, 71.72, 73, 81, 82, 83, 84, 85 and 89). The test has a diagnostic sensitivity of 98.2% and a diagnostic specificity of 100% and analytical specificity: 100%. The analytical sensitivity of this test is 100% when the number of copies is 1,000 or 10,000 depending on the type of HPV. The Laboratory has carried out external quality control of the SEAP.
Pre-surgical evaluation:
Those patients with an abnormal cytological result and / or positive HPV tests were referred to the PTGI consultations of Clínico San Carlos Hospital for evaluation according to the Cervical Cancer Prevention Guidelines issued by the Spanish Association of Cervical Pathology and Colposcopy (AEPCC) in 2006 and 2014. These patients underwent colposcopy with biopsy if necessary +/- determination of HPV. Patients diagnosed with HSIL / CIN 2+ who met the inclusion criteria were submitted to cervical conization and subsequently enrolled in the study after signing the informed consent, approved by ethics commission.
We will take into account the date of administration of the first dose of vaccine. The types of vaccines administered can be: Bivalent vaccine (includes genotypes 16/18), Tetravalent (includeds genotypes 6, 11, 16 and 18) both funded in the region in different years, or not funded (Nonavalent vaccine; includes genotypes: 6, 11, 16, 18, 31, 33, 45, 52 and 58). To define the time of vaccination around the conization date, the administration of the first dose of vaccine will be taken into account.
Surgical treatment:
Excisional therapy was performed in the operating room on a scheduled basis under local analgesia and sedation. After infiltration with local anesthetic and vasoconstrictor in the 4 quadrants of the cervix, excisional therapy with diathermic loop is performed under colposcopy control, obtaining the piece in a single specimen. The piece is oriented with a long thread at 12:00 h, it is introduced in formaldehyde and send to pathological anatomy for deferred study. In all cases, immediate endocervical curettage post-treatment was performed.
Clinical follow-up:
The first revision is made 30 days after surgery where patient is informed of histological results and the date on first control post-treatment based on the diagnosis.
Following the protocol of the AEPCC, in case of non-involvement of margins and negative endocervical curettage, the patient comes after 6 months from the intervention to perform the first post-surgery control with co-test. In case of positive endocervical curettage or margin involvement, the first post-surgery control will be performed at 4 months with cotest + endocervical study and colposcopy. Persistent disease is defined as the presence of cytological alteration and / or HPV infection in the first post control performed at 4-6 months after excisional therapy. These patients are excluded from the study, since only those in which both tests are negative will be included.
Subsequently, a new co-test was performed at 12 months, 24 months and 36 months after the first post-surgery control. After 3 years of negative testing, the patient is returned to the current cervical cancer-screening program.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: ANDREA CASAJUANA PEREZ
- Phone Number: 0034 913 30 30 01
- Email: andreamercedes.casajuana@salud.madrid.org
Study Locations
-
-
-
Madrid, Spain, 28040
- Recruiting
- Hospital Clinico San Carlos
-
Contact:
- ANDREA CASAJUANA PEREZ
- Phone Number: 0034 913 30 30 01
- Email: andreamercedes.casajuana@salud.madrid.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Women older than 18 years who received excisional therapy due to HSIL /CIN injury confirmed histologically.
- Women who sign informed consent.
- Patients with negative results in the first post-surgery control.
- Patients who have received HPV vaccination and provide vaccination card.
Exclusion Criteria:
- Women who do not wish or cannot give their informed consent and / or do not comply with the requirements of the study.
- Patients treated by an indication other than HSIL/CIN.
- Patients under immunosuppression conditions.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
vaccinated women
|
. Patients diagnosed with HSIL / CIN 2+ who met the inclusion criteria were submitted to cervical conization and subsequently enrolled in the study after signing the informed consent, approved by ethics commission. We will take into account the date of administration of the first dose of vaccine. The types of vaccines administered can be: Bivalent vaccine (includes genotypes 16/18), Tetravalent (includeds genotypes 6, 11, 16 and 18) both funded in the region in different years, or not funded (Nonavalent vaccine; includes genotypes: 6, 11, 16, 18, 31, 33, 45, 52 and 58). To define the time of vaccination around the conization date, the administration of the first dose of vaccine will be taken into account. |
non vaccinated woman
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recurrence
Time Frame: 2 years
|
defined as the existence of persistent HPV infection and / or presence of cytological abnormality and / or presence of SIL / CIN / VaIN of any grade.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Age, type of virus, degree of injury, variables related to demographic and histological data of the patient, date of 1st dose of vaccine.
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
General Publications
- Kang WD, Choi HS, Kim SM. Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)? Gynecol Oncol. 2013 Aug;130(2):264-8. doi: 10.1016/j.ygyno.2013.04.050. Epub 2013 Apr 26.
- FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007 May 10;356(19):1915-27. doi: 10.1056/NEJMoa061741.
- Ghelardi A, Parazzini F, Martella F, Pieralli A, Bay P, Tonetti A, Svelato A, Bertacca G, Lombardi S, Joura EA. SPERANZA project: HPV vaccination after treatment for CIN2. Gynecol Oncol. 2018 Nov;151(2):229-234. doi: 10.1016/j.ygyno.2018.08.033. Epub 2018 Sep 6. No abstract available.
- Pieralli A, Bianchi C, Auzzi N, Fallani MG, Bussani C, Fambrini M, Cariti G, Scarselli G, Petraglia F, Ghelardi A. Indication of prophylactic vaccines as a tool for secondary prevention in HPV-linked disease. Arch Gynecol Obstet. 2018 Dec;298(6):1205-1210. doi: 10.1007/s00404-018-4926-y. Epub 2018 Oct 10.
- Velentzis LS, Brotherton JML, Canfell K. Recurrent disease after treatment for cervical pre-cancer: determining whether prophylactic HPV vaccination could play a role in prevention of secondary lesions. Climacteric. 2019 Dec;22(6):596-602. doi: 10.1080/13697137.2019.1600500. Epub 2019 Apr 29.
- Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G; HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009 Jul 25;374(9686):301-14. doi: 10.1016/S0140-6736(09)61248-4. Epub 2009 Jul 6. Erratum In: Lancet. 2010 Sep 25;376(9746):1054.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ISM-190623
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HPV Infection
-
Lee's Pharmaceutical LimitedUnknownCervical HPV-16 and / or HPV-18 InfectionChina
-
Sinocelltech Ltd.RecruitingHPV Infection Vaccine Safety SCT1000China
-
Ulla Bonde van ZwolUniversity of Southern Denmark; Region of Southern Denmark; MCM Vaccines B.V.Unknown
-
PDS Biotechnology Corp.CompletedHigh-risk HPV Infection and Biopsy-proven CIN1United States
-
Capital Medical UniversityUnknown
-
Kenya Medical Research InstituteMerck Sharp & Dohme LLC; University of WashingtonCompletedHPV Infection | HPV Vaccine | HIV-1-infectionKenya
-
Merck Sharp & Dohme LLCCompletedHPV Infections
-
University of Alabama at BirminghamCompleted
-
Merck Sharp & Dohme LLCSuspended
-
University of WashingtonActive, not recruiting
Clinical Trials on HPV vaccine
-
University of PretoriaUniversity of StellenboschActive, not recruiting
-
Sun Yat-sen UniversityRecruitingPremature Ovarian Failure | Menstrual DisorderChina
-
Xiamen UniversityXiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise...CompletedCervical Cancer | Cervical Intraepithelial NeoplasiaChina
-
Simon DobsonMinistry of Health, British ColumbiaCompletedCervical Cancer | Genital WartsCanada
-
Jun ZhangXiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise...Completed
-
H. Lee Moffitt Cancer Center and Research InstituteFlorida Department of Health; Health Choice NetworkRecruitingHuman Papilloma Virus (HPV) VaccineUnited States
-
Jun ZhangXiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise...Active, not recruiting
-
Laval UniversityCompletedHuman PapillomavirusCanada
-
Xiamen Innovax Biotech Co., LtdCompleted
-
Xiamen UniversityXiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise...Active, not recruitingCervical Cancer | Cervical Intraepithelial Neoplasia | Condylomata AcuminataChina